Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders

European Neuropsychopharmacology

Volumn 9, Issue SUPPL. 3, 1999, Pages

  Nutt, David J ^a   Forshall, Sam ^a   Bell, Caroline ^a   Rich, Ann ^a   Sandford, John ^a   Nash, Jon ^a   Argyropoulos, Spilios ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Anxiety disorders; Depression; Pharmacokinetics; Selective serotonin reuptake inhibitors; Serotonergic receptors; Tryptophan depletion

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; POSTSYNAPTIC RECEPTOR; PRESYNAPTIC RECEPTOR; REBOXETINE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN; VENLAFAXINE;

ANXIETY NEUROSIS; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; MENTAL DISEASE; PANIC; PRIORITY JOURNAL; SEROTONIN UPTAKE; SEROTONINERGIC TRANSMISSION; TRYPTOPHAN METABOLISM;

ANXIETY DISORDERS; BRAIN; DEPRESSIVE DISORDER; HUMANS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPSES;

EID: 0032792358     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(99)00030-9     Document Type: Conference Paper

References (24)

1. Aberg-Wistedt A., Hasselmark L., Stain-Malmgren R., Aperia B., Kjellman B.F., Mathe A.A. Serotonergic vulnerability in affective disorder: A study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr. Scand. 97:1998;374-380.
2. Barr L.C., Goodman W.K., McDougle C.J., Delgado P.L., Heninger G.R., Charney D.S., Price L.H. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;309-317.
3. Baumann P., Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: A look behind the mirror. Int. Clin. Psychopharmacol. 10:(Suppl. 1):1995;10-15.
4. Benkelfat C., Ellenbogen M.A., Dean P., Palmour R.M., Young S.N. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch. Gen. Psychiatry. 51:1994;687-697.
5. Boyer W.F., Feighner J.P. Pharmacokinetics and drug interactions. Feighner J.P., Boyer W.F. Selective Serotonin Reuptake Inhibitors. 1991;81-88 John Wiley, Chichester, UK.
6. Delgado P.L., Charney D.L., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry. 47:1990;411-418.
7. Goodman W.K., Price L.H., Rasmussen S.A., Delgado P.L., Heninger G.R., Charney D.S. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch. Gen. Psychiatry. 46:1989;36-44.
8. Hyttel J. Pharmacological characterisation of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 9:(Suppl. 1):1994;19-26.
9. Laws D., Ashford J.J., Anstee J.A. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr. Scand. 81:1990;185-189.
10. Lecrubier Y., Bakker A., Dunbar G., Judge R. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr. Scand. 95:1997;145-152.
11. Lesch K.P. 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology (Berl). 106:1992;111-117.
12. Marshall R.D., Schneier F.R., Fallon B.A., Knight C.B., Abbate L.A., Goetz D., Campeas R. An open trial of paroxetine in patients with non-combat-related, chronic posttraumatic stress disorder. J. Clin. Psychopharmacol. 18:1998;1-18.
13. Milne R.J., Goa K.L. Citalopram: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs. 41:1991;450-477.
14. Nutt D.J., Glue P., Lawson C., Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch. Gen. Psychiatry. 47:1990;917-925.
15. Öström M., Eriksson A., Thorson J., Spigset O. Fatal overdose with citalopram. Lancet. 348:1996;339-340.
16. Overo K.F. Preliminary studies of the pharmacokinetics of citalopram in man. Eur. J. Clin. Pharmacol. 14:1978;69-73.
17. Personne M., Persson H., Sjöberg G. Citalopram toxicity. Lancet. 350:1997;518-519.
18. Rickels K., Amsterdam J., Clary C., Fox I., Schweizer E., Weise C. A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta Psychiatr. Scand. Suppl. 350:1989;117-123.
19. Rocca P., Fonzo V., Scotta M., Zanalda E., Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr. Scand. 95:1997;444-450.
20. Smeraldi E., Diaferia G., Erzegovesi S., Lucca A., Bellodi L., Moja E.A. Tryptophan depletion in obsessive-compulsive patients. Biol. Psychiatry. 40:1996;398-402.
21. Smith K.A., Fairburn C.G., Cowen P.J. Relapse of depression after rapid depletion of tryptophan. Lancet. 349:1997;915-919.
22. Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial. JAMA. 280:1998;780-783.
23. Uphouse L. Multiple serotonin receptors: Too many, not enough, or just the right number? Neurosci. Biobehav. Rev. 21:1997;679-698.
24. Van der Kolk B.A., Dreyfuss D., Michaels M., Shera D., Berkowitz R., Fisler R., Saxe G. Fluoxetine in posttraumatic stress. J. Clin. Psychiatry. 55:1994;517-522.